226 related articles for article (PubMed ID: 24139237)
1. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations.
Sun H; Sun C; Xiao W
Cytokine; 2014 Jan; 65(1):33-41. PubMed ID: 24139237
[TBL] [Abstract][Full Text] [Related]
2. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
Esen F; Deniz G; Aktas EC
Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
[TBL] [Abstract][Full Text] [Related]
3. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
4. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta.
Eriksson M; Meadows SK; Wira CR; Sentman CL
J Leukoc Biol; 2004 Sep; 76(3):667-75. PubMed ID: 15178706
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of TIGIT and PD-1 expression on NK cells during the course of normal pregnancy.
Wang Y; Li D; Yu T; Hu M; Xing J; Bai S; Qu W; Tong X
Immunol Lett; 2021 Feb; 230():42-48. PubMed ID: 33359535
[TBL] [Abstract][Full Text] [Related]
8. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
[TBL] [Abstract][Full Text] [Related]
9. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
10. A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta.
Lee HM; Kim KS; Kim J
Cell Immunol; 2014 Jul; 290(1):52-61. PubMed ID: 24879062
[TBL] [Abstract][Full Text] [Related]
11. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
12. Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL-1β, IFN-β, and IL-15 Pathways.
Mattiola I; Pesant M; Tentorio PF; Molgora M; Marcenaro E; Lugli E; Locati M; Mavilio D
J Immunol; 2015 Sep; 195(6):2818-28. PubMed ID: 26276870
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of natural killer cell in tumor tissue and peripheral blood of oral squamous cell carcinoma.
Dutta A; Banerjee A; Saikia N; Phookan J; Baruah MN; Baruah S
Cytokine; 2015 Dec; 76(2):123-130. PubMed ID: 26372424
[TBL] [Abstract][Full Text] [Related]
14. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989
[TBL] [Abstract][Full Text] [Related]
15. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells.
Quatrini L; Vacca P; Tumino N; Besi F; Di Pace AL; Scordamaglia F; Martini S; Munari E; Mingari MC; Ugolini S; Moretta L
J Allergy Clin Immunol; 2021 Jan; 147(1):349-360. PubMed ID: 32417134
[TBL] [Abstract][Full Text] [Related]
17. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation.
Schierloh P; Alemán M; Yokobori N; Alves L; Roldán N; Abbate E; del C Sasiain M; de la Barrera S
Immunology; 2005 Dec; 116(4):541-52. PubMed ID: 16313368
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
[TBL] [Abstract][Full Text] [Related]
19. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.
Yu J; Wei M; Becknell B; Trotta R; Liu S; Boyd Z; Jaung MS; Blaser BW; Sun J; Benson DM; Mao H; Yokohama A; Bhatt D; Shen L; Davuluri R; Weinstein M; Marcucci G; Caligiuri MA
Immunity; 2006 May; 24(5):575-90. PubMed ID: 16713975
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
